TheraVet announced the positive safety and efficacy results for BIOCERA-VET? used in cimentoplasty as palliative treatment for canine osteosarcoma. BIOCERA-VET?, TheraVet?s bone substitute, was assessed in a prospective non-controlled multicentric clinical study in client-owned dogs suffering from osteosarcoma. Twelve dogs were treated by a percutaneous cimentoplasty using BIOCERA-VET? as palliative treatment of osteosarcoma and followed up for 6 months. The main objective of the study was to assess the effect of BIOCERA-VET?cimentoplasty on dog pain, using scores such as veterinary score pain and validated owner questionnaires CBPI (Canine Brief Pain Inventory) and VAS pain. Quality of life was assessed by the owner with the CBPI questionnaire. Also, the complications and the adverse events were collected as safety evaluation. In this study, BIOCERA-VET? was used alone, non-combined with chemotherapy. Among the animals satisfying the different follow-up visits, BIOCERA-VET? cimentoplasty improved significantly the pain as measured by VAS pain and CBPI. Indeed, 67% of the dogs at 1 month and 50% at 2 and 6 months experienced a reduction of at least 50% in pain. The same reduction levels were measured with the pain severity (PSS) and with the pain interference with the function (PIS) scores of the CBPI, although slightly less. Quality of Life was improved in 78% of the dogs at 1 month and in 50% of the dogs at 2 and 6 months. BIOCERA-VET? was well-tolerated with a low rate of complications Indeed, only 3 complications (25%) were reported: one dog displayed at surgical site infection, one dog displayed a swelling at the surgical site and one dog suffered from a fracture at the site of the tumor. This low rate of complications is very promising. First, in a similar approach of cimentoplasty associated with PMMA in a multimodal management of canine osteosarcoma, complication rate reached 75% (including wound swelling, surgical site infection, exacerbation of the lameness, thromboembolism in combination with cough and anemia) for only limited benefit on lameness. Second, the fracture incidence of 8% in the BIOCERA-VET? study compares very favorably with the incidence of pathological fractures in canine osteosarcoma is ~40%. Taken together, the results of this first multicentric prospective study demonstrate the important potential of cimentoplasty associated with BIOCERA-VET? inrelieving pain and improving the quality of life of dogs suffering from osteosarcoma.